Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial
Authors:
- 5 December 2022
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 17 (1) , 249-261
Abstract
Background Severe alcoholic hepatitis (SAH) has high 90-day mortality. Prednisolone therapy has shown modest survival benefits over placebo at 28 but not 90 days. Fecal microbial transplantation (FMT) has shown promise in these patients. We compared the efficacy and safety of the two therapies in SAH patients. Methods Steroid eligible SAH patients were randomized in an open-label study to prednisolone (n = 60) 40 mg/day for 28 days (assessed at day-7 for continuation) or healthy donor FMT (n = 60) through naso-duodenal tube, daily for seven days. Primary outcome of study was day-90 survival. Results Patients in prednisolone and FMT arms were comparable at baseline (discriminant function score 65 ± 16.2 and 68 ± 14, MELD score 17.1 and 16.5, respectively). Of 120 patients, 112 [prednisolone-57; FMT-55] completed trial. As per intention-to-treat analysis, 90-day survival was achieved by 56.6% (34/60) patients in prednisolone and 75% (45/60) in FMT group (p = 0.044, FMT HR = 0.528, 95%CI 0.279–0.998). Secondary outcome of 28-day survival [78.33% (47/60) and 88.33% (53/60) (p = 0.243, FMT HR = 0.535, 95%CI 0.213–1.34)] with comparable severity scores over time between both arms. Infections accounted for 11 (19.3%) and 2 (3.6%) deaths in prednisolone and FMT groups, respectively (p = 0.01). Path-tracing showed a slow establishment of microbiota and alpha diversity (Shannon index) improvement by day-28 (p = 0.029). FMT resulted in 23 new taxa by day-28, reduction from baseline in pathogenic taxa [Campylobacter (19-fold, p = 0.035), anaerobes (Parcubacteria, Weisella and Leuconostocaceae)], and increase of Alphaproteobacteria [~ sevenfold, p = 0.047] and Thaumarcheota (known ammonia oxidizer, p = 0.06). Lachnospiraceae (p = 0.008), Prevotella and Viellonella communities in gut favored survival (p < 0.05). Conclusion In severe alcoholic hepatitis, FMT is safe and improves 90-day survival and reduces infections by favorably modulating microbial communities. It can be a useful alternative to prednisolone therapy. Graphical abstractKeywords
This publication has 25 references indexed in Scilit:
- Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis ConsortiaGastroenterology, 2016
- Intestinal microbiota contributes to individual susceptibility to alcoholic liver diseaseGut, 2015
- Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta‐analysis of randomized trialsLiver International, 2015
- Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and OutlookGastroenterology, 2015
- Prednisolone or Pentoxifylline for Alcoholic HepatitisNew England Journal of Medicine, 2015
- Dysbiosis‐induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in miceHepatology, 2014
- Control of pathogens and pathobionts by the gut microbiotaNature Immunology, 2013
- The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insightsMolecular and Cellular Endocrinology, 2011
- Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient dataGut, 2010
- The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroidsHepatology, 2007